Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital

Pharmacogenomics (PGx) is a growing field within precision medicine. Testing can help predict adverse events and sub-therapeutic response risks of certain medications. To date, the US FDA lists over 280 drugs which provide biomarker-based dosing guidance for adults and children. At Arkansas Children...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Pritmohinder S., Yu, Feliciano B., Porter-Gill, Patricia A., Boyanton, Bobby L., Allen, Judy C., Farrar, Jason E., Veerapandiyan, Aravindhan, Prodhan, Parthak, Bielamowicz, Kevin J., Sellars, Elizabeth, Burrow, Andrew, Kennedy, Joshua L., Clothier, Jeffery L., Becton, David L., Rule, Don, Schaefer, G. Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150685/
https://www.ncbi.nlm.nih.gov/pubmed/34064668
http://dx.doi.org/10.3390/jpm11050394
Descripción
Sumario:Pharmacogenomics (PGx) is a growing field within precision medicine. Testing can help predict adverse events and sub-therapeutic response risks of certain medications. To date, the US FDA lists over 280 drugs which provide biomarker-based dosing guidance for adults and children. At Arkansas Children’s Hospital (ACH), a clinical PGx laboratory-based test was developed and implemented to provide guidance on 66 pediatric medications for genotype-guided dosing. This PGx test consists of 174 single nucleotide polymorphisms (SNPs) targeting 23 clinically actionable PGx genes or gene variants. Individual genotypes are processed to provide per-gene discrete results in star-allele and phenotype format. These results are then integrated into EPIC- EHR. Genomic indicators built into EPIC-EHR provide the source for clinical decision support (CDS) for clinicians, providing genotype-guided dosing.

Ejemplares similares